Biopharma may have to wait for Brexit details

With U.K. and EU governments reaching a draft Brexit deal on Tuesday, the future of drug regulation in the U.K. and the country’s participation in EU science programs may take months to hammer out even after the text of the agreement is published.

The deal, reported by multiple news outlets citing undisclosed government sources, is expected to cover citizens' rights post-Brexit, details of the U.K. payment to the EU, and plans for the border between Northern Ireland and Ireland. Inclusion of details regarding the customs arrangement could mitigate growing concerns around the availability and transit of medicines between the U.K. and EU...